Form 4: SpringWorks Therapeutics Chief Medical Officer Disposes of Shares Following Merck KGaA Merger Completion

SpringWorks Therapeutics' Chief Medical Officer, James Cassidy, disposed of all beneficial ownership in the company's securities following the completion of its acquisition by Merck KGaA for $47.00 per share.

Summary

• SpringWorks Therapeutics, Inc. (SWTX) completed its merger with Merck KGaA, Darmstadt, Germany, through its wholly owned subsidiary EMD Holdings Merger Sub, Inc., effective July 1, 2025.
• As a result of the merger, each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash.
• James Cassidy, Chief Medical Officer, disposed of 81,731 shares of common stock, which included 47,762 shares underlying restricted stock units (RSUs).
• Mr. Cassidy also disposed of 21,654 performance share units (PSUs).
• Additionally, Mr. Cassidy disposed of stock options to purchase 135,000 shares at an exercise price of $27.64, 80,000 shares at $38.40, and 50,615 shares at $43.00.
• Following the reported transactions, Mr. Cassidy holds 0 shares of common stock, performance share units, or stock options in SpringWorks Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The filing reflects the successful completion of a merger, providing a cash payout to shareholders and a structured transition for equity award holders, which is generally a positive outcome for the acquired company's investors.

Positives

• The merger provides a definitive cash payout of $47.00 per share to SpringWorks Therapeutics shareholders.
• Outstanding restricted stock units (RSUs) and performance share units (PSUs) were converted into cash-based awards, with vesting terms generally continuing under the new parent company.
• Vested stock options were converted into cash, providing liquidity to option holders based on the difference between the merger consideration and the exercise price.

Negatives

• SpringWorks Therapeutics, Inc. ceased to be an independent publicly traded company, becoming a wholly owned subsidiary of Merck KGaA.
• Any outstanding stock options with an exercise price greater than the $47.00 merger consideration were cancelled for no consideration or payment.

Future Outlook

SpringWorks Therapeutics, Inc. is now a wholly owned subsidiary of Merck KGaA. Unvested cash-based RSU and option awards will generally continue to vest in accordance with their original terms, with a specific provision for 50% of each then-unvested tranche to vest on the nine-month anniversary of the closing date, subject to the holder's continued employment with Parent.

Industry Context

This transaction represents a consolidation event within the biotechnology and pharmaceutical industry, where larger entities like Merck KGaA acquire companies such as SpringWorks Therapeutics to expand their therapeutic portfolios and pipelines. Such acquisitions are common strategies for growth and market expansion.

Comparison to Industry Standards

• The cash-out merger structure is a standard approach for acquisitions in the pharmaceutical and biotechnology sectors, providing immediate liquidity to the acquired company's shareholders.
• The treatment of equity awards, converting them to cash-based awards with continued vesting contingent on employment, is a common mechanism used in mergers to retain key talent post-acquisition.

Stakeholder Impact

• Shareholders of SpringWorks Therapeutics received $47.00 in cash for each share, providing a clear and immediate return on their investment.
• Employees holding equity awards, such as James Cassidy, had their awards converted into cash-based awards, with continued vesting contingent on their employment with the acquiring entity, Merck KGaA.

Next Steps

• Continued employment of certain executives, such as James Cassidy, with Merck KGaA to facilitate the vesting of their converted cash-based equity awards.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, Form 4, Insider Transaction, Beneficial Ownership, Equity Awards, Restricted Stock Units, Performance Share Units, Stock Options, Biotechnology, Pharmaceuticals, Chief Medical Officer